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Introduction
Cis-regulatory sequences control when, where and with 
what intensity genes are expressed. Key to this control is 
the recruitment of transcription factors (TFs) that bind 
to regulatory sequences, such as promoters, enhancers, 
repressors  and  insulators.  These  target  sequences  are 
spread  across  DNA.  Probably  reflecting  the  secondary 
structure properties of looped DNA within a nucleus, there 
are confirmed cases of cis-regulatory elements up to about 
106 bp distant from the transcription initiating promoter 
of a gene [1]. Mutations in TF binding sites (TFBSs) can 
disrupt the essential protein-DNA inter  actions required 
for  the  appropriate  patterning  or  magnitude  of  gene 
expression. Similarly, mutations can disrupt other sequence-
specific regulatory controls, such as elements regulating 
RNA splicing or stability. Although much emphasis in the 
age of exome sequencing has been placed on variation 
within  protein-encoding  sequences,  it  is  apparent  that 
regulatory sequence disruptions will become a key focus 
as full genome sequences become widely accessible for 
medical genetics research.
The  emerging  collection  of  cis-regulatory  variations 
that cause human disease or altered phenotype is grow-
ing [2-4]. Reports identify cis-acting, expression-altering 
mutations  observed  within  introns,  far  upstream  of 
genes, at splicing sites or within microRNA target sites. 
For example, cis-regulatory mutations have roles in hemo-
philia,  Gilbert’s  syndrome,  Bernard-Soulier  syndrome, 
irritable  bowel  syndrome,  beta-thalassemia,  cholesterol 
homeostasis  and  altered  limb  formation  [5-11].  The 
number of cis-regulatory variants reported in the litera-
ture has continued to expand over the past 2 years [12-18]. 
In addition, compilations of cis-regulatory variants have 
been reported [4,19,20]. Although many studies associate 
cis-regulatory  variations  with  phenotype,  it  is  rare  for 
researchers  to  conclusively  demonstrate  causality.  The 
strongest  causal  evidence  is  obtained  with  transgenic 
approaches, in cell culture or animal models, to identify 
phenotypes  triggered  by  such  variations  [21,22].  The 
impor  tance of regulatory changes is nevertheless apparent.
Ultimately  genetics  researchers  seeking  regulatory 
muta  tions are best served by high-quality annotations of 
the  human  genome,  with  clearly  designated  functional 
elements. Most routinely expressed protein coding exons 
are  known,  making  initial  identification  of  protein-
altering  genetic  changes  simple.  In  contrast,  despite 
ongoing  ambitious  efforts  to  annotate  non-coding 
genome features, the inventory of cis-regulatory elements 
is  far  from  complete.  Large-scale  chromatin  immuno-
precipitation  (ChIP)  experiments  provide  the  vast 
majority of data, eclipsing the compiled information of 
the past 25 years derived from targeted studies of specific 
regulatory elements. Many of the new ChIP-derived data, 
however,  highlight  segments  of  DNA  (about  200  to 
1,000 bp) containing a functional element rather than a 
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hyper  sensitivity analysis specifies regions likely to contain 
regulatory  elements  [23].  Thus,  the  experi  mentally 
defined regions must be coupled to additional methods 
to assess the potential for a specific DNA variation to 
affect  gene  activity.  Some  of  the  key  data  resources 
reporting  regulatory  regions  and  delineating  specific 
elements are introduced below.
Our perspective is biased to elements with sequence-
specific properties, including TFBSs, microRNA, splice-
regulating  target  sequences,  and  immediate  core-
promoter  sequences  critical  to  the  initiation  of  trans-
cription (Figure 1). Although diverse types of cis-regula-
tory variations will become accessible for future studies, 
at present the bioinformatics resources for the study of 
variation within TFBSs are the most accessible and there-
fore our primary focus here.
We begin by outlining an example workflow. Then we 
step through elements of the workflow in greater detail, 
including a brief overview of the discovery of sequence 
variations from high-throughput sequence data. Finally, 
we review TFBS identification approaches and strategies 
for  the  prioritization  of  cis-regulatory  variations  for 
further analysis. We conclude with a brief mention of two 
emerging experimental techniques that may be used in 
the future to associate cis-regulatory variants and their 
gene  targets.  Our  aim  is  to  assist  medical  genetics 
researchers  to  identify  potential  regulatory  variants 
within non-coding regions of the human genome.
A workflow for identifying disease-causing 
cis-regulatory variants
An  example  workflow  for  the  identification  of  cis-
regulatory TFBSs linked to a disease is outlined in the 
following section, and is illustrated in Figure 2. Given a 
set  of  high-throughput  sequencing  data  from  an 
individual, the short sequences are individually aligned to 
a reference human genome sequence. Sets of overlapping 
reads  are  analyzed  to  determine  the  genotype  at  each 
position  for  which  sufficient  aligned  sequences  are 
available. Common polymorphisms and rare variants are 
distinguished  relative  to  the  reference  genome.  For 
familial studies, variations segregating with the pheno-
type can be determined, and researchers emerge with a 
set of disease-causing candidates. For each candidate for 
causality,  it  is  desirable  to  assess  the  potential  for  the 
sequence mutation to disrupt a biological function. Many 
researchers  will  be  content  to  focus  on  the  subset  of 
candidates  predicted  to  create  a  severe  alteration  in  a 
protein sequence. Software for the prediction of damag-
ing  changes,  including  modules  from  SIFT  [24]  and 
PolyPhen-2 [25], identify variants that substitute amino 
acids  expected  to  cause  changes  in  protein  structure, 
alter a critical position in a protein domain, or change an 
amino  acid  of  high  evolutionary  conservation.  Many 
researchers will stop at this step.
For those interested in potential cis-regulatory changes, 
a panel of computational analyses can be performed on 
the candidate variations. At the core of the processes is a 
Figure 1. Classification of the regulatory sequences in a gene that can be modified by genetic variation. The four colored groups reflect 
mutations that have a deleterious impact on gene transcription (class 1 in red), splicing (class 2 in blue), RNA stability (class 3 in orange) and 
translation (class 4 in green). A fifth class, non-coding RNA interaction sites, is not shown as sites can occur throughout DNA and RNA sequences.
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Page 2 of 14method  for  TFBS  prediction  based  on  position  weight 
matrices, known alternatively as position-specific scoring 
matrices  (PSSMs,  called  ‘possums’).  Each  matrix  is  a 
quantitative description of the frequency of each nucleo-
tide  at  each  position  of  a  set  of  known  TFBSs  for  a 
specific TF. Methods related to the generation and appli-
ca  tion of the matrices are described below. Such matrices 
can be useful for predicting the biochemical capacity of a 
TF  to  interact  with  a  specific  DNA  sequence,  but  the 
models  have  no  capacity  to  assess  whether  a  specific 
DNA segment in the genome will be accessible to the TF. 
Thus, TFBS predictions are almost always combined with 
one  or  more  ‘filters’  to  specify  regions  of  the  genome 
expected  to  function  as  cis-regulatory  regions.  Such 
filters may include data about epigenetic modifications or 
DNA  accessibility,  the  observed  binding  of  TFs,  or 
sequence  conservation  (phylogenetic  footprinting).  The 
process will be explored in greater detail in the following 
sections.
For researchers who do not have bioinformatics tools 
in the laboratory, the comparison of coordinate positions 
between  datasets  (between  variants  and  TFBSs,  or 
variants and regulatory region filters) can be done using 
the Galaxy tools (a set of web-based, fundamental bio-
informatic  tools  for  extracting  and  manipulating  text-
based data) [26]. Tutorials and help documentation are 
accessible through the Galaxy wiki.
Overview of variant identification from 
high-throughput sequence data
The  first  step  in  the  identification  of  disease-causing 
regulatory variants in individual genomes requires both 
sequencing technologies and software for processing the 
data to distinguish technical errors from true variations. 
Figure 2. Overview of a workflow for cis-regulatory variant detection. The boxes represent steps in the workflow, and the italicized 
descriptions under the boxes correspond to analysis resources listed in Table 1. For identification of regulatory elements and regions, the order 
in the workflow may be changed without loss of information. Common variants, flagged by an asterisk, may be eliminated from the analysis or 
alternatively flagged for later tracking.
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development  [27,28]  and  it  is  unlikely  that  they  will 
become stable for several years. We will therefore begin 
this  section  by  outlining  general  concepts  for  working 
with high-throughput sequencing data, before highlight-
ing the most promising recent developments. In Table 1 
we provide specific examples of well-maintained open-
resource databases and software, including resources for 
conceptual classes of software mentioned below.
The  process  of  identifying  a  variation  or  mutation 
anywhere in a DNA sequence begins with mapping the 
sequenced DNA of interest to a reference human genome 
sequence. Sequencing generates DNA segments termed 
reads.  Given  a  combination  of  technological  sequence 
errors  and  genetic  variation,  coupled  to  the  extensive 
sequence repetition in the human genome, many reads 
cannot  be  uniquely  mapped  to  a  single  reference  co-
ordinate region. False variations may arise, in part, from 
the incorrect mapping of reads. One can identify and set 
aside reads that map to multiple locations in the genome 
with nearly equal alignment quality, denoting such cases 
as potential sources of variant-calling errors.
Once a set of uniquely mapped reads is determined, the 
next step in an analysis pipeline is the identification of 
genetic variations from the reference genome based on 
the shared characteristics of overlapping reads. Greater 
Table 1. Data and analysis tools (open-source)
Genetic variant data
  dbSNP  http://www.ncbi.nlm.nih.gov/projects/SNP/
  1000 Genomes  http://www.1000genomes.org/
  HapMap Project  http://hapmap.ncbi.nlm.nih.gov/
Coding variant characterization
  SIFT  http://sift.jcvi.org/
  Polyphen-2  http://genetics.bwh.harvard.edu/pph2/
ChIP-Seq data 
  Gene Expression Omnibus (GEO)  http://www.ncbi.nlm.nih.gov/geo/
  ENCODE project  http://genome.ucsc.edu/ENCODE/
  PAZAR  http://www.pazar.info/
Motif discovery
  Meme-ChIP  http://meme.nbcr.net/
TFBS profiles
  JASPAR  http://jaspar.genereg.net/
  PAZAR  http://www.pazar.info/
TFBS databases   
  PAZAR  http://www.pazar.info/
  ORegAnno  http://www.oreganno.org/
TFBS variant characterization
  Variant effect predictor  http://uswest.ensembl.org/tools.html
  is-rSNP  http://www.genomics.csse.unimelb.edu.au/is-rSNP/
  rSNP-MAPPER   http://genome.ufl.edu/mapper/
RNA-Seq splice analysis 
  TopHat  http://tophat.cbcb.umd.edu/
  MapSplice  http://www.netlab.uky.edu/p/bioinfo/MapSplice
Splice enhancer discrimination
  SFmap  http://sfmap.technion.ac.il/
  ESE Finder  http://rulai.cshl.edu/tools/ESE
Data management and visualization
  Galaxy (tool kit)  http://galaxy.psu.edu/
  UCSC Genome Browser  http://genome.ucsc.edu/
  Ensembl BioMart  http://www.ensembl.org/biomart/martview/
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sequenced) is advantageous for more reliable statistical 
confidence  in  the  determination  of  a  genotype  at  a 
position. But depth is not the only influence to consider, 
as systematic mismapping of reads can result in false calls 
even with many reads overlapping. The complex nature 
of the data causes genotype ‘calling’ software to be one of 
the  most  rapidly  changing  components  of  the  variant 
identi  fication process, with continuously improving methods 
emerging in a constant stream of publications [29].
Given  a  set  of  variations,  it  is  common  to  classify 
observed variants as common or rare. Common varia-
tions, such as single nucleotide polymorphisms (SNPs), 
occur with at least a minimum frequency in a population 
(commonly a minimum allele frequency of 1% is applied). 
Lists of common variants can be obtained from HapMap 
[30,31], dbSNP [32], and 1000 Genomes [33] databases, 
but  recently  dbSNP  has  been  consolidating  data  from 
most of the major resources and may be sufficient for 
most  users.  Please  note  that  contrary  to  the  formal 
meaning of SNP, the dbSNP resource also includes rare 
variations.
After  filtering  common  variants  from  a  dataset,  the 
remaining variants are categorized as rare (and conse-
quently considered by many researchers as more likely to 
be causal for extremely rare phenotypes) [34]. Although 
it  has  been  frequent  practice  in  genome  sequencing 
studies  of  familial  disorders  to  exclude  all  previously 
observed  variants  (both  rare  variants  and  poly  mor-
phisms),  it  is  our  perception  that  the  rapidly  growing 
collection of genome sequence data and variants makes it 
increasingly likely that such screens will exclude relevant 
causal mutations. For each individual genome sequenced, 
the researcher emerges with a categorized set of variants - 
common  polymorphisms,  previously  reported  rare 
variants,  and  novel  variants.  A  recent  technical  report 
presents  a  framework  for  variation  discovery  and 
genotyping that reflects the above concepts [35].
For each individual sequenced, the number of variants 
in each of the three categories will be large. The number 
of variants to consider can be reduced by focusing on 
variations  that  segregate  with  a  phenotype  in  a  family 
study [36]. In addition, it has been common practice to 
focus on mutations predicted to severely alter an encoded 
protein, such as nonsense mutations. However, there is 
now a growing interest in the impact of variants located 
in the non-coding portion of a genome. The following 
sections highlight methods that researchers can use to 
focus on variants located within cis-regulatory elements, 
in particular TFBSs.
Detection of cis-regulatory elements
The identification of variants situated in TFBSs is depen-
dent on the identification of bona fide TFBSs, which is a 
challenge.  Common  approaches  include  three  primary 
components: (i) databases of known TFBSs; (ii) compu-
tational prediction of TFBSs using software models; and 
(iii)  prediction  of  regions  likely  to  contain  TFBSs  -  a 
process we term ‘filtering’. The first two components will 
be introduced below, followed by the introduction of a 
method  highly  related  to  the  second  component,  for 
predicting the subset of putative regulatory variants likely 
to alter the binding energy of a TF-DNA interaction. The 
third component - filtering - is described in the subse  quent 
section.
Databases of experimentally defined TFBSs
At  some  point  in  the  future,  there  will  be  a  reliable 
database  reporting  every  TFBS  in  the  human  genome, 
the  gene  promoter(s)  that  each  acts  on,  the  biological 
condition(s)  under  which  each  TFBS  is  active  and  the 
TF(s) that interact with each. There have been attempts 
over previous decades to develop databases housing such 
information; nevertheless, none of these are ideal, and all 
are constrained by a lack of high-resolution experimental 
data. One of the most widely known databases of this 
kind  is  Transfac,  which  operates  under  a  commercial 
access model [37]. Open-access proponents have imple-
mented alternative databases. The ORegAnno database 
aims  to  collect  a  broad  range  of  TFBS  data,  using  a 
convenient data format that allows rapid submission [38]. 
The PAZAR database has a more complex data model, 
which allows rich annotation of the evidence underlying 
each  TFBS,  as  well  as  a  full  description  of  the  TFBS 
(conditions, interacting TFs, cell types, and so on) [39]. 
There are many databases restricted to lower resolution 
data,  such  as  ChIP  with  sequencing  (ChIP-Seq),  that 
specify regions of DNA bound by a TF (such data are also 
contained  by  ORegAnno,  PAZAR,  and  the  ENCODE 
data center at the University of California, Santa Cruz - 
UCSC [40]).
The  data  from  the  open-access  collections  can  be 
downloaded for high-throughput comparisons of TFBS 
positions  with  variant  positions.  The  logistics  of  such 
comparisons are described in the subsection below on 
‘Assessing the impact of sequence variations on TF-DNA 
interactions’.
Computational prediction of TFBSs
Although a small set of TFBSs has been experimentally 
validated as functional and recorded in reference data-
bases, this probably represents an insignificant portion of 
the entire set of TFBSs in the human genome. We must 
therefore, for now, rely heavily on computational methods 
to  predict  TFBSs.  A  description  of  the  most  common 
method follows.
A TFBS motif model summarizes what is known, at the 
sequence level, about the properties of a set of TFBSs for 
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be used to scan a DNA sequence of interest in ‘windows’ of 
the same length as the regulatory element that the motif 
model  represents.  A  computer  program  incrementally 
moves along a DNA sequence in 1 bp steps, returning a 
score at each step to indicate the strength with which each 
window of the DNA sequence matches the motif. The top 
scoring  windows  are  the  most  similar  to  the  consensus 
sequence of the TFBS bound by a TF.
As  defined  above,  the  most  commonly  used  motif 
models for predicting the location of TFBSs are termed 
PSSMs. A single TF will recognize similar DNA sequences, 
but will tolerate variation from the consensus TF binding 
site  pattern  [41].  A  PSSM  is  generated  from  a  DNA 
sequence alignment of experimentally confirmed TFBSs 
for a TF (Figure 3). Such alignments are commonly gener-
ated  using  pattern  discovery  software  such  as  MEME 
[42]. Once aligned, a matrix is created that reports the 
frequency of each nucleotide (A, C, G, and T) at each 
position of the alignment - the resulting matrix is called a 
position  frequency  matrix  (PFM).  The  last  step  in 
obtaining  a  PSSM  is  to  convert  the  PFM  using  a 
logarithmic function that weights the frequency of each 
nucleotide  at  each  position  by  the  frequency  of  that 
nucleotide in the genomic background (in many software 
implementations the default background frequency is set 
to  0.25  for  each  nucleotide)  [43].  The  widths  of  most 
published TFBS PSSMs fall in the range 8 to 14 bp. The 
scores produced are analogous to binding energies [44] 
and can thus be considered a prediction of the strength of 
association of a TF protein with a specific DNA sequence. 
Software for scanning DNA sequences using the matrix 
models is widely available through computer program-
ming  modules  (TFBS  [45]),  downloadable  software 
(RSAT  [46])  or  online  websites  (ORCAtk  [39]).  Active 
discussions are ongoing in the bioinformatics field about 
how the models can be improved in light of the increasing 
amount of TFBS data arising from ChIP-Seq studies [47].
Figure 3. Transcription factor binding site (TFBS) motif model. Sequences known to be bound by a specific transcription factor (for example, 
SPI1) are aligned. A position frequency matrix (PFM) is generated by counting the number of times each type of nucleotide occurs at each position 
of the alignment. The PFM is then converted to a log-scale position-specific scoring matrix (PSSM). The score of any DNA sequence window, having 
the same length as the matrix, is calculated by summing the corresponding nucleotide values from the PSSM. The PFM may also be represented as 
a binding site logo, depicting the nucleotide properties of the TFBSs.
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such as JASPAR [48], PAZAR [49] or Uniprobe [50]. Until 
recently, the number of TFs with PSSMs has increased 
slowly,  but  high-throughput  laboratory  approaches  for 
the profiling of TF-bound sequences have resulted in a 
striking  increase  in  the  number  and  quality  of  PSSMs 
[48,50]. Such high-throughput experimental data typically 
arise from either in vivo ChIP, such as ChIP-Seq [51], or 
from  in  vitro  protein  binding  studies,  such  as  protein 
binding  microarrays  [52].  In  ChIP-Seq  experiments, 
protein-DNA complexes are isolated using an antibody 
specific to the TF of interest, and the recovered DNA 
sequence is determined. For protein binding microarrays, 
double-stranded DNA of known sequence is affixed to 
the microarray surface and the adherence of a fluores-
cently labeled protein preparation of a TF (or frequently 
just the DNA-binding domain from a TF) is measured; 
the bound sequences are subsequently analyzed to deter-
mine the DNA sequence patterns targeted by the protein. 
Driven  by  these  new  technologies,  the  number  of  TFs 
with  PSSMs  in  the  open  access  JASPAR  database  has 
increased fivefold in the past year, rising from 100 to 500 
PSSMs (about 25% of the 1,500 vertebrate TFs are now 
represented).
The  prediction  of  functional  regulatory  elements  by 
PSSMs,  although  having  good  sensitivity  (most  true 
positives are found), suffers from poor specificity (many 
false positives are predicted) [53]. With regard to speci-
ficity, a simple biochemical explanation of the problem is 
that  the  TFBS-predicting  PSSMs  determine  sequences 
that a TF can bind in vitro, but in vivo the DNA may not 
be accessible to the TF. For instance, a predicted TFBS 
may be buried in compact chromatin. Thus, a prediction 
of a TFBS in isolation has limited relevance to the proba-
bility that a segment in the human genome will function 
as  a  cis-regulatory  element.  Approaches  to  reduce  the 
specificity  problems  by  filtering  are  discussed  in  the 
section  below  on  ‘Refining  cis-regulatory  predictions 
with filters’.
The  same  concepts  underlying  the  use  of  PSSMs  to 
predict TFBSs apply to most motif discrimination methods 
for sequence-specific regulatory elements, ranging from 
splice  enhancers  to  translation  start  sites  [54-56].  We 
focus here principally on TFBSs, which are DNA-related; 
more  information  about  RNA-related  cis-regulatory 
elements can be found in a recent review [57].
Assessing the impact of sequence variations on TF-DNA 
interactions
Given a PSSM for a specific TF, and both the reference 
DNA  sequence  and  the  DNA  sequence  containing  a 
variant, one can predict whether the variant alters the 
DNA sequence in a manner that strengthens or weakens 
the biochemical interaction of the TF with the DNA. The 
reference  sequence  and  the  variant  sequence  are  both 
scanned and scored by the PSSM model. If the difference 
between observed scores is large, and at least one of the 
sequence isoforms is a known TFBS or is assigned a score 
that exceeds a user defined threshold for TFBS presence, 
the  variation  is  predicted  to  have  a  functional  impact. 
Such thresholds depend on the software used. The impact 
of  the  variant  is  calculated  as  the  reported  difference 
between  the  two  scores.  The  higher-scoring  allele  is 
predicted to be bound by the TF with greater affinity. The 
calculation of PSSM score differences has two directions 
as  variants  have  the  potential  to  either  knock  out  or 
create a TFBS. The action of the variant is captured by 
the  sign  (+/-)  of  the  score  difference  in  the  above 
calculation.
Software  for  prediction  of  TFBS  alterations  by 
sequence variations includes the variant effect predictor, 
is-rSNP, and rSNP-MAPPER tools [58-60]. Although use-
ful for identifying mutations overlapping known TFBSs, 
in the absence of additional information, such compari-
sons have limited value for predicted TFBSs (including all 
cases of de novo generation of TFBSs) [61,62], as the high 
rate  of  false  TFBS  predictions  by  PSSMs  remains  un-
addressed. In the following section we outline additional 
data  that  may  be  incorporated  to  improve  TFBS 
prediction specificity.
Similar  allele  comparison  programs  have  been 
developed to predict altered microRNA target sites [63] 
and splicing elements [64].
Refining cis-regulatory predictions with filters
As  stated  above,  predictions  of  TFBSs  are  unreliable 
because  of  a  high  false  positive  prediction  rate  (poor 
specificity). Predictions of cis-regulatory elements can be 
overlaid with genome annotations or experimental data 
to focus attention on the regions that are more likely to 
be functional [18,65]. An increase in specificity can be 
obtained  by  filtering  predicted  regulatory  elements 
against complementary data, such as: (i) gene structure 
(topology  filters);  (ii)  regions  of  sequence  conservation 
(phylogenetic  footprinting);  (iii)  TF-bound  regions 
defined experimentally (such as ChIP-Seq for TFs); or (iv) 
struc  turally accessible (or inaccessible) regions (such as 
ChIP-Seq for epigenetic marks or DNase I hyper  sensi-
tivity analyses). All the filters can be used individually or 
in combination, where it is functionally relevant; their 
main  purpose  is  to  add  supporting  evidence  that  a 
predicted  regulatory  element  is  func  tional.  Although 
biologically relevant filters can dramatically increase the 
specificity of cis-regulatory element predictions, there 
may  be  a  loss  in  sensitivity  with  the  use  of  multiple 
filters,  so  it  is  recommended  that  a  researcher  assess 
results  based  on  one  filter  before  incorporating 
additional filters.
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The activity of many cis-regulatory elements is spatially 
dependent  (see  Figure  1  for  locations  of  cis-regulatory 
elements).  For  instance,  splice-regulating  elements  are 
positioned adjacent to splice sites (reviewed in [57]) and 
the target sequences for non-coding RNA, such as micro-
RNAs, may be preferentially situated within 3’ untrans-
lated regions [66]. Specific types of TFBSs within the core 
and proximal promoters, such as the TATA box and the 
downstream  proximal  element,  are  topologically  con-
strained  to  occupy  a  specific  location  relative  to  the 
transcription start site (TSS) [67]. Genome annotations 
and laboratory data can specify TSS locations, allowing 
researchers to focus on variants situated with functionally 
relevant  spatial  localization.  Existing  annotations  from 
high-throughput  profiling  of  5’  capped  RNA  [68]  and 
cDNA sequencing in genome annotation databases can 
delineate such regions. Increasingly, however, the anno-
tation  of  exons  is  defined  by  RNA-Seq  experiments 
applied to patient samples [69].
Each of these genomic data types can be retrieved as 
genomic  positions  from  either  a  genome  browser  (for 
example, using the Galaxy tools [26] or Ensembl BioMart 
[70]) or from laboratory data, and should be chosen for 
their  relevance  to  the  type  of  regulatory  element  of 
interest. The positions of topological annotations can 
be  compared  with  the  positions  of  the  predicted 
regulatory elements, using data analysis tools such as 
those  that  the  Galaxy  system  provides.  Where 
topological  features  are  proximal  to  or  overlap  with 
corresponding  variant-altered  regulatory  element 
predictions,  the  variants  may  have  greater  reliability 
than predictions lacking such support.
Conservation filters (phylogenetic footprinting)
Sequence conservation in the human genome can focus 
attention  on  regions  with  functional  roles,  a  process 
termed  phylogenetic  footprinting.  Using  conservation 
scores based on multiple species alignments, such as the 
Phylogenetic  P-values  (PhyloP)  [71]  (obtainable  using 
the Galaxy system or directly from the UCSC genome 
anno  tation database), researchers can restrict attention 
to  regions  more  likely  to  have  sequence-specific 
function.  Although  there  is  evidence  of  functional 
regulatory  sequences  being  conserved  over  moderate 
periods of evolution [72], there is also ample evidence of 
plasticity  in  regulatory  sequences  [73].  Conservation-
based filters can enrich for functional sequences, but, as 
for  all  filters,  functionally  relevant  sequences  without 
sequence con  ser  vation may be lost [65]. If the position 
of  a  predicted  variant-altered  regulatory  element 
overlaps  a  conserved  region,  then  the  cis-regulatory 
potential of the variant is considered to have functional 
support.
TF binding filters
Increasing  access  to  high-throughput  profiles  of  ChIP 
data is key to improved regulatory sequence studies. In 
the ChIP method, a specific antibody targeting a protein 
of interest is used to recover DNA sequences bound by 
the  protein  [51].  The  nucleotide  sequence  of  the 
recovered DNA is increasingly being identified by high-
throughput  sequencing,  resulting  in  the  procedure 
known as ChIP-Seq. Regions containing a site bound by a 
targeted protein are identified in ChIP-Seq experiments 
as  displaying  a  higher  abundance  of  sequence  reads 
recovered relative to a control set of data at a specific 
position in the genome. The method delivers two impor-
tant advances for cis-regulatory element detection over 
past methodologies. First, it can be applied to detect TF 
or  transcription  co-activator  bound  regions  across  the 
entire genome of any species that has been sequenced 
[74]. Second, the results provide improved resolution of 
the boundaries for functional regulatory regions, provid-
ing the researcher with a refined search space for deter-
mining the active cis-regulatory element(s) in the region.
We focus here on two classes of ChIP-Seq experiments - 
those  that  profile  interactions  between  a  sequence-
specific binding TF with DNA and those proteins that 
associate in a sequence-independent manner with regu-
latory regions (discussed in the next section).
With ChIP-Seq it is common to map the protein-DNA 
interactions to regions as small as about 300 bp. Although 
useful, the study of genetic variants requires more precise 
mappings of individual TFBSs. Thus, ChIP-Seq-defined 
regions  are  used  as  filters  to  refine  the  computational 
predictions  generated  with  PSSMs.  If  no  PSSM  is 
available for the TF, the ChIP-Seq regions can be used in 
a  motif  discovery  program  (such  as  MEME  [42])  to 
generate a PSSM that can be used in turn to predict TFBS 
positions. As with the previous filters, for each predicted 
TFBS-altering  variant,  those  overlapping  a  ChIP-Seq-
delineated region can be considered of sufficient relia-
bility to motivate further laboratory studies.
Regulatory region accessibility filters
In addition to data pertaining to the sequence-specific 
binding  of  TFs,  ChIP-Seq  data  can  be  obtained  that 
delineate regions of a genome that are likely to contain 
elements involved in gene regulation. Such approaches 
may be based on antibodies that recognize specific epi-
genetic marks associated with cis-regulatory activity (for 
example,  histone  modifications),  or  antibodies  that 
recog  nize proteins, such as co-activators, associated with 
regulatory sequences that interact with DNA-bound TFs. 
DNase  I  accessibility  analysis  likewise  reveals  regions 
with potential regulatory roles.
Studies  focused  on  individual  histone  modifications 
have  shown  that  certain  marks,  such  as  H3K4me3, 
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such as H3K27me3, are pronounced at silent promoters 
[75]. Combined with cis-regulatory predictions, combi-
nations of epigenetic marks can be used to more precisely 
delineate regulatory regions with potential active roles. 
Focusing cis-regulatory element predictions proximal to 
or within epigenetic regions associated with active regu-
lation improves the specificity of cis-regulatory element 
prediction [76,77].
The transcriptional co-activator p300, a component of 
many regulatory protein associations, has been targeted 
in ChIP-Seq studies to define transcriptional enhancers - 
genomic regions containing multiple TFBSs that collect-
ively enhance transcription [78]. Visel et al. [78] took 86 
regions associated with p300, tested them for regulatory 
activity  in  vivo,  and  found  that  88%  of  the  predicted 
regions were active regulatory regions. They found that 
using p300-predicted enhancer regions reduced the rate 
of false-positive predictions made by alternative methods 
by four-fold. Given the difficulty in obtaining high quality 
antibodies to proteins, and as the number of co-activators 
(about 101) is small relative to the number of sequence-
specific TFs (about 103), it is likely that ChIP-Seq data for 
the complete set of co-activators will become a preferred 
means of delineating likely regulatory regions active in 
each cell type.
In both classes of ChIP-Seq experiments, the defined 
regulatory regions from the ChIP-Seq studies can be used 
to select the predicted regulatory elements and variants 
most likely to affect cis-regulatory function.
Examples of applied regulatory sequence variation 
prediction
Use of such filters as outlined above for the prediction of 
regulatory variants is starting to emerge in the literature. 
As interest rises with respect to the non-coding regula-
tory portions of the genome, we can expect to see more 
examples similar to the two we briefly outline below.
A  key  paper  has  recently  emerged,  highlighting  the 
potential  power  behind  combining  SNP  identification 
and different lines of regulatory evidence. Ernst et al. [79] 
combined  non-coding  disease-associated  SNPs  derived 
from  multiple  genome-wide  association  studies  with 
epigenetic  evidence  for  potential  regulatory  enhancer 
regions, and TFBS predictions. Non-coding SNPs were 
found to significantly overlap with enhancers predicted 
by epigenetic analyses, and the SNP-containing en  han-
cers tended to be detected in cell types relevant to the 
disease.  For  instance,  SNPs  associated  with  systemic 
lupus  erythematosus  coincided  with  enhancer  regions 
detected  in  lymphoblastoid  cells.  The  authors  further 
investigated  these  regulatory  variant  predictions  by 
examining the potential of these disease-associated SNPs 
to  interrupt  or  strengthen  predicted  TFBSs  in  the 
overlapping enhancer regions, such as an ETS1 binding 
motif in the aforementioned lupus example.
Oishi et al. [80] assessed multiple layers of regulatory 
evidence, such as topology, conservation, TFBS predic-
tion, and TF binding, for regulatory variation prediction. 
They  focused  on  the  KLF5  gene  locus  because  of  the 
potential  role  of  its  upstream  regulatory  programs  in 
hypertension. Genotyping array experiments on 20 hyper-
tensive individuals identified an associated SNP located 
upstream of a KLF5 transcription initiation site. The SNP 
was  observed  to  be  situated  at  a  position  conserved 
between humans, mice, and rats. Bioinformatics analysis 
of TFBS motifs predicted an overlapping binding site for 
MEF2a,  which  was  subsequently  confirmed  by  ChIP 
analysis (in human aortic smooth muscle cells). Experi-
mental analysis demonstrated that the SNP altered the 
MEF2a binding affinity.
These two examples highlight the effectiveness of using 
regulatory  annotation  data  and  predictions  to  focus 
atten  tion on variants that might have an impact on gene 
regulation.
Case studies of filter-based support of regulatory variant 
predictions
We provide two examples of disease-associated variants 
and  some  data  filters  that,  if  these  variants  were  un-
known,  could  be  overlaid  to  support  a  cis-regulatory 
variant prediction (Figures 4 and 5). These case reviews 
were  in  part  chosen  because  they  lend  themselves  to 
viewing in the UCSC Genome Browser. The first variant 
(Figure  4)  is  causal  for  hemophilia  B  Leyden  and  the 
second (Figure 5) is associated with protection against a 
disease; the latter is a case of a mutation creating a new 
regulatory  element.  We  selected  genome  annotations 
from  four  tracks  available  on  the  UCSC  Genome 
Browser: (i) distance from a TSS (topology) - RefSeq gene 
track; (ii) two databases for literature- derived TFBSs - 
PAZAR and ORegAnno tracks; (iii) mammalian conser-
vation - PhyloP track; and (iv) known sequence variants - 
dbSNP  track.  The  UCSC  Genome  Browser  provides 
instructions  for  researchers  wanting  to  add  their  own 
data tracks to a display, or wishing to extract data from 
tracks to apply to their own analysis.
A  classic  example  of  an  inactivating  mutation  in  a 
regulatory sequence is the disruption of a binding site for 
the TF HNF4A present in the promoter of the Factor IX 
endopeptidase gene (F9) involved in blood coagulation 
(Figure  4).  The  mutation  is  causal  for  hemophilia  B 
Leyden [5]. A single nucleotide change of T to A at the 
most strongly conserved position of the HNF4A binding 
site results in reduced transcription of F9. The position of 
the  variation  relative  to  the  regulatory  element  is 
displayed in the HNF4A PSSM sequence logo (Figure 4b). 
Figure 4c depicts a view of the region surrounding the 
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PAZAR track shows the location of binding sites in the 
region, one of which is for HNF4A, and the RefSeq track 
illustrates that the binding sites are proximal to the gene’s 
TSS. The PhyloP mammalian conservation track reports 
sequence conservation at the HNF4a binding site, contri-
buting  support  to  this  site  as  a  functional  regulatory 
element. For this region no SNP has been reported, as 
represented by the empty track for dbSNP at the bottom 
of  Figure  4c.  As  dbSNP  was  originally  intended  as  a 
database  for  sequence  polymorphisms  and  has  only 
recently started to acquire rare variants, the empty track 
signifies that this variant may not be common.
Activating  mutations  may  create  binding  sites.  A 
variation in the promoter of the Alox15 gene creates a 
binding site for the TF SPI1 (Figure 5), which results in 
elevated expression of the gene. The SPI1 TFBS-creating 
variation has been linked to protection against athero-
sclerosis [81]. Comparing Figure 4 with Figure 5 we see 
that a TFBS common to the population (Figure 4, HNF4A) 
has  various  data  annotations  supporting  its  functional 
importance,  whereas  a  TFBS  that  has  been  newly 
generated (Figure 5, SPI1) lacks most such annotations. 
The  RefSeq  track  shows  the  variant  to  be  within  the 
promoter region of the Alox15 gene. However, consistent 
with  a  variant  creating  a  new  regulatory  element,  no 
overlapping  TFBS  has  been  annotated  in  either  of  the 
PAZAR or ORegAnno databases, nor is there evidence of 
significant sequence conservation at the location of this 
element. The position of the variation is reported by the 
dbSNP  track,  even  though  it  is  not  a  polymorphism, 
which  suggests  this  variant  is  not  a  technical  error. 
However, in this instance it may be present owing to the 
dataset the variant was derived from being uploaded to 
dbSNP. In a case such as this, where a variant is predicted 
to have created a new regulatory element, the only useful 
data filters are likely to be topological, unless a researcher 
has  access  to  ChIP-Seq  data  generated  from  the 
individual(s) carrying the variant.
With the conclusion of a workflow, such as that over-
viewed  here,  a  researcher  will  possess  a  refined  list  of 
putative cis-regulatory variants. Determining the causality 
Figure 4. Visualization of a causal cis-regulatory mutation for hemophilia B Leyden that alters an HNF4A binding site in the promoter of 
the Factor IX gene. In this example, at least three sets of data support the hypothesis that the variant modifies a functional transcription factor 
binding site (TFBS): a TFBS database, proximity to a transcription start site (TSS; topology filter), and conservation data. (a) Variant location in base 
pairs between the regulatory element and the TSS. (b) Logo of nucleotide binding preferences for HNF4a. The mutated position in the HNF4A 
binding site is highlighted. The height of the letters ‘T’ and ‘A’ at that position indicate the frequency of a thymine or an adenine nucleotide in HNF4a 
TFBSs. The thymine at position 8 is strongly maintained among known TFBSs. (c) UCSC Genome Browser view highlighting four of the data types 
that may be used to support the prediction of a cis-regulatory variant. Red and gold tracks, PAZAR and ORegAnno databases of TFBSs; dark blue 
track, mammalian conservation; black track, data from dbSNP.
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currently lies in the hands of experimental researchers.
The emerging challenge: associating 
variant-altered TFBSs with target genes
Unaddressed in the workflow reviewed up to this point is 
the  challenge  of  defining  the  associations  between 
potential  cis-regulatory  variants  and  target  genes. 
Possibly as a result of DNA looping, regulatory sequences 
can act specifically on distant genes, skipping intervening 
genes in some cases [82,83]. Within the nucleus, DNA 
sequences  that  are  not  proximal  in  sequence  may  be 
brought into proximity by the three-dimensional looping 
of chromatin. Emerging methods that detect such DNA 
proximity (such as the Hi-C method described in [84,85]) 
may  provide  data  suitable  for  integration  into  future 
bioinformatics  methods  for  predicting  the  impact  of  a 
variant. Alternatively, methods are emerging that specify 
the  edges  of  accessible  DNA  regions,  features  termed 
insulators. Such methods, largely based on ChIP-based 
experiments  using  antibodies  to  the  insulator  binding 
protein  CTCF,  could  be  used  to  determine  which 
promoter regions are accessible to a TF bound between 
insulator sequences [86,87]. As these techniques are still 
maturing,  bioinformatics  approaches  continue  to  asso-
ciate regulatory elements and putative target genes based 
on distance measurements (the closest gene is the target), 
or  through  predictions  arising  from  linkage  dis  equi-
librium or differential gene expression studies. However, 
we  anticipate  a  time  in  the  future  when  three-dimen-
sional maps of nuclei can be generated experimentally.
Conclusions and future directions
At present the tools for the study of genome-wide regu-
latory  sequence  variations  are  limited,  leading  resear-
chers to focus on variations predicted to alter genomic 
regions with well developed annotation - protein-coding 
sequences.  This  is  due  in  part  to  the  nature  of  the 
regulatory target and in part the availability of data. The 
cis-regulatory elements are short in length, widespread 
Figure 5. Visualization of a cis-regulatory mutation creating a functional SPI1 binding site in the promoter of ALOX15. In this example, 
the variant occurs near the transcription start site (TSS; topology filter), there is slight evidence that the site of the variant is conserved against 
mutations, and the variant is found in dbSNP; thus, it is unlikely to be a technical error. (a) Variant location. (b) Logo of nucleotide binding 
preferences for SPI1. The altered position of the ALOX15 sequence relative to a SPI1 binding site is highlighted. The mutation converts the 
nucleotide at that position from a cysteine to the most strongly conserved nucleotide in all SPI1 binding sites - a thymine. (c) UCSC Genome 
Browser view as in Figure 4.
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genomic  landmarks  -  they  can  be  both  proximal  and 
distal to their gene targets. Computational predictions of 
regulatory  elements,  in  turn,  are  faced  with  extracting 
short and variable signal from a large genomic space, in 
which  there  is  a  mixture  of  functional  elements  and 
apparent randomly occurring non-functional sequences. 
Regulatory  predictions  are  further  complicated  by  the 
fact  that  the  cellular  environment  and  stage  of 
development affects the functional activity of regulatory 
elements  -  an  element  that  is  active  in  one  cellular 
context may not be active in another, an aspect important 
to the study of disease. However, from the current era of 
high-throughput  technology,  we  can  anticipate  an 
increased  understanding  of  the  biological  dynamics  of 
cis-regulatory elements to feed into and improve compu-
tational  algorithms  predicting  the  locations  of  cis-
regulatory elements. With improved predictions we will 
increase our ability to predict cis-regulatory-associated 
variants  and  their  functional  impact  on  the  regulatory 
elements they coincide with.
The ability to look with increased resolution at the non-
coding space of the genome has recently encouraged an 
increasing  number  of  laboratories  to  investigate  the 
impact of cis-regulatory-associated variants on disease, 
which  as  a  result  has  motivated  the  development  of 
bioinformatics tools for linking variants with regulatory 
elements. Bioinformaticians are still in the early stages of 
developing methods to integrate high-throughput regula-
tory  data,  such  as  ChIP-Seq  and  RNA-Seq,  with  regu-
latory element prediction, variant calling, and databases 
of  known  regulatory  elements  and  variants.  At  the 
current time, researchers are best served by following a 
workflow such as that described here. However, a critical 
mass of interest in regulatory variants is being reached, 
and automated workflows will become publicly available 
in the near future.
The increased affordability of whole-genome sequenc-
ing has dramatically expanded the potential for studying 
cis-regulatory-related diseases in a familial context. The 
added power of having related genomes to study segre-
gation  of  familial  sequence  variants  with  a  phenotype 
dramatically  improves  the  ability  to  predict  disease-
associated cis-regulatory variants. We anticipate that the 
next few years will see a rapid expansion of such family-
associated studies.
Use  of  the  aforementioned  filters  and  tools  in  a 
workflow,  as  outlined  here,  coupled  to  the  improved 
detec  tion  of  causal  variants  provided  by  genome-wide 
data  for  multiple  related  individuals,  provides  medical 
genetic  researchers  with  the  means  to  prioritize  the 
potential regulatory impact of a given a set of variants. In 
the future, integrated tools will consolidate the analysis 
process,  bringing  diverse  analysis  methods  and  data 
sources into a self-contained workbench for regulatory 
variation analysis.
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